Compared to the TP53 wild-type group, the TP53-mutated group had a higher proportion of ductal-type breast cancer (86.0% vs. 76.6%; p = 0.016), more frequent histologic grade III tumors (61.6% vs. 28.9%, p < 0.001), an increased rate of LVI (34.5% vs. 17.4%, p < 0.001), and a higher Ki67 index (73.8% vs. 31.4%, p < 0.001). This evidence concerns the gene TP53 and breast cancer.